SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Dont Pass Man who wrote (38545)1/9/2017 12:59:04 PM
From: allatwwk   of 63307
 
IMMU's work is costing the company money. But so is venBio. In their filings, they said should their slate prevail, they will be reimbursed for their expenses.

This fight is a worthy one, because the cost/benefit is positive, even if IMMU slate prevails (as it should be a better slate than current).

But this fight is not cheap and the IMMU bank account will certainly notice.

fwiw, the IMMU bank account will also notice the cost of a new CEO. Anyone entering the picture is going to want $$ up front. Especially since the stock available is rather tight if venBio succeed in having no new shares authorized (my guess, they probably wish they'd offered up 10million new shares, compared to the 40mil offered by the first IMMU proposal)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News